2015


To access this material please log in or register

Register Authorize
2015/№3

Evaluating the efficacy of drug and surgery methods in treatment of IHD patients with pronounced left ventricular dysfunction

Chernyavsky A. M., Efremova O. S., Ruzmatov T. M., Efendiev V. U.
Federal State Budgetary Institution, "Academician E. N. Meshalkin Novosibirsk Research Institute of Circulatory Pathology" of the RF Ministry of Health Care, Rechkunovskaya 15, Novosibirsk 630055

Keywords: CAD, treatment, prognosis, surgical methods

DOI: 10.18087/rhj.2015.3.2067

Background. Determination of the optimum tactics for treatment of IHD patients with low LV EF is still an open issue. Aim. To compare efficacy of drug and surgical methods of treatment in IHD patients with LV EF ≤35 %. Materials and methods. This prospective, randomized study included 80 IHD patients with LV EF ≤35 %. 40 patients received an optimum drug therapy, and 40 patients underwent the coronary bypass (CB) surgery. Evaluation of the clinical status and EchoCG parameters was performed at baseline, before discharge from the hospital, and at 1, 3 and 7 years. Results. For 7 years, both treatments provided improvement of the patients’ clinical condition. CB proved superior in the first 3 years. In-hospital mortality was observed only with the surgical treatment (7.5 %). As distinct from the optimum drug treatment, CB provided a considerable improvement of EchoCG parameters in the first year of follow-up. Beginning from the third year, both groups showed signs of progressive LV remodeling.
  1. Нечесова Т. А., Коробко И. Ю., Кузнецова Н. И. Ремодели­рова­ние левого желудочка: патогенез и методы оценки. Медицинские новости. 2008;11:7–14.
  2. Chaitman BR, Ryan TJ, Kronmal RA et al. Coronary Artery Surgery Study (CASS): comparability of 10 year survival in randomi­zed and randomizable patients. J Am Coll Cardiol. 1990 Nov;16 (5):1071–8.
  3. Varnauskas E. Twelve-year follow-up of survival in the randomized European Coronary Surgery Study. N Engl J Med. 1988 Aug 11;319 (6):332–7.
  4. Justice AC, Dombrowski E, Conigliaro J et al. Veterans Aging Cohort Study (VACS): Overview and description. Med Care 2006 Aug;44 (8 Suppl 2):S13–24.
  5. The CONSENSUS Trial Study Group. Effects enalapril on morta­lity in severe congective heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987 Jun 4;316 (23):1429–35.
  6. Effects of enalapril on survival in patients with reduced left ventri­cular ejection fractions and congestive heart failure. N Engl J Med. 1991 Aug 1;325 (5):293–302.
  7. Ambrosy AP, Butler J, Ahmed A et al. The use of digoxin in patients with worsening chronic heart failure: reconsidering an old drug to reduce hospital admissions. J Am Coll Cardiol. 2014 May 13;63 (18):1823–32.
  8. The Сardiac Insufficiensy Bisoprolol Study II (CIBIS-II): a randomized trial. Lancet. 1999 Jan 2;353 (9146):9–13.
  9. Effect of metoprolol CR / XL in chronic heart failure: Metoprolol CR / XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999 Jun 12;353 (9169):2001–7.
  10. Kulbertus H. Study of the month. The RALES study (randomized aldactone evaluation study. Rev Med Liege. 1999 Sep;54 (9):770–2.
  11. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. New Engl J Med. 2001 Dec 6;345 (23):1667–75.
  12. Krum H, Roecker EB, Mohacsi P et al. Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS study. JAMA. 2003 Feb 12;289 (6):712–8.
  13. Granger CB, McMurray JJ, Yusuf S et al. Effects of the candesartan in patients with chronic heart failure and reduced left ventricular systolic function and intolerant to ACE inhibitors: the CHARM-Alternative trial. Lancet. 2003 Sep 6;362 (9386):772–6.
  14. McMurray JJ, Ostergren J, Sweedberg K et al. Effects of the cande­sartan in patients with chronic heart failure and reduced left ventri­cular systolic function treated with an ACE inhibitor: the CHARM-Added trial. Lancet. 2003 Sep 6;362 (9386):767–71.
  15. Shibata MC, Flather MD, Bohm M et al. Study of Effects Nebivolol Intervention on Outcomes and Rehospitalization in Seniors with Heart Failure (SENIORS). Rationale and design. Int J Cardiol. 2002 Nov;86 (1):77–85.
  16. GISSI-HF investigators, Tavazzi L, Maggioni AP et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HT trial): a randomized, double-blind, placebo-controlled trial. Lancet. 2008 Oct 4;372 (9645):1231–9.
  17. Everitt BS, Pickles A. Statistical aspects of the design and analysis of clinical trials. – London: Imperial College Press, 2004. – 336 р.
  18. Fox K, Garcia MA, Ardissino D et al. Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J. 2006 Jun;27 (1):1341–81.
  19. Smith SC Jr, Blair SN, Bonow RO et al. AHA / ACC Scientific Statement: AHA / ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation. 2001 Sep 26;104 (13):1577–9.
  20. Di Mattia DG, Di Biasi P, Salati M et al. Surgical treatment of left ventricular post-infarction aneurysm with endoventriculoplasty: late clinical and functional results. Eur J Cardiothorac Surg. 1999 Apr;15 (4):413–8.
  21. Бурдина Е. Н., Шопин А. Н., Соболев А. В. и др. Различия в геометрии левого желудочка у здоровых лиц, оптимизация формы или начало ремоделирования. Фундаментальные исследования. 2010;3:30–6.
  22. Волкова И. И. Ремоделирование сердца и сосудов при ишемической болезни сердца. Патология кровообращения и кардиохирургия. 2010;4:96–8.
  23. Рекомендации по диагностике и лечению хронической сердечной недостаточности (2005): рабочая группа Европейского общества кардиологов по диагностике и лечению хронической сердечной недостаточности. Рациональная Фармакотерапия в Кардиологии. 2006;2 (2):71–101.
  24. Shah PK. Preservation of cardiac extracellular matrix by passive myocardial restraint: an emerging new therapeutic paradigm in the prevention of adverse remodeling and progressive heart failure. Circulation. 2005 Aug 30;112 (9):1245–7.
  25. Yamaguchi A, Adachi H, Kawahito K et al. Left ventricular reconstruction benefits patients with dilated ischemic cardiomyipathy. Ann Thorac Surg. 2005 Feb;79 (2):456–61.
  26. Чернявский А. М., Марченко А. В., Караськов А. М. Хирур­гическое лечение ишемической болезни сердца, осложнённой сердечной недостаточностью. – Нск: Академическое издательство «Гео», 2010. – c. 85–91.
  27. Алшибая М. М., Арутюнян В. Б., Коваленко О. А. др. Отда­лён­ные результаты геометрической реконструкции левого желудочка в сочетании с реваскуляризацией миокарда. Научно-медицинский вестник Центрального Черноземья. 2007;29:31–7.
  28. Bax JJ, Wijns W, Cornel JH et al. Accuracy of currently available techniques for prediction of functional recovery after revasculari­zation in patients with left ventricular dysfunction due to chronic coro­nary artery disease: comparison of pooled data. J Am Coll Cardiol. 1997 Nov 15;30 (6):1451–60.
  29. Емельянов В. А. Диастолическая дисфункция левого желудочка у больных постинфарктным кардиосклерозом и ее медикаментозная коррекция на амбулаторном этапе. Дис. … канд. мед. наук. – Новосибирск, 2005. – 174 c.
  30. Шелковникова Т. А. Влияние эффективности контроля артериального давления на отдельные результаты аортокоронарного шунтирования. Автореф. дис. … канд. мед. наук. – Томск, 2007. – 140 c.
  31. Williams DO. Treatment delayed is treatment denied. Circulation. 2004 Apr 20;109 (15):1806–8.
  32. Акчурин P. C., Рахмат-Заде Т. М., Скридлевская Е. А. Влияние реваскуляризации миокарда на сократительную функцию миокарда левого желудочка у больных с ишемической болезнью сердца и хронической сердечной недостаточностью. Кардиология. 2006;46 (8):33–6.
  33. Yusuf S, Zucker D, Peduzzi P et al. Effect of coronary artery bypass graft surgery on survival: overview of 10‑year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet. 1994 Aug 27;344 (8922):563–70.
  34. Loop FD, Lytle BW, Cosgrove DM et al. Influence of the internal-mammary-artery graft on 10‑year survival and other cardiac events. N Engl J Med. 1986 Jan 2;314 (1):1–6.
  35. Lytle BW, Blackstone EH, Sabik JF et al. The effect of bilateral internal thoracic artery grafting on survival during 20 postoperative years. Ann Thorac Surg. 2004 Dec;78 (6):2005–12.
  36. Taggart DP, D’Amico R, Altman DG. Effect of arterial revascularisation on survival: a systematic review of studies comparing bilateral and single internal mammary arteries. Lancet. 2001 Sep 15;358 (9285):870–5.
  37. Wijns W, Kolh Ph, Danchin N et al. Рекомендации по реваскуляризации миокарда. Рациональная Фармакотерапия в Кардиологии. 2011;7 (3 Прил): 2–60.
  38. Eagle KA, Guyton RA, Davidoff R et al. ACC / AHA 2004 guideline update for coronary artery bypass graft surgery: summary article: a report of the American Collegeof Cardiology / American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). Circulation. 2004 Aug 31;110 (9):1168–76.
Chernyavsky A. M., Efremova O. S., Ruzmatov T. M. et al. Evaluating the efficacy of drug and surgery methods in treatment of IHD patients with pronounced left ventricular dysfunction. Russian Heart Journal. 2015;14 (3):145–152

To access this material please log in or register

Register Authorize
Ru En